PCI-24781

DRUG4 trials

Sponsors

Pharmacyclics LLC., Massachusetts General Hospital

Conditions

Hodgkin DiseaseLeukemiaLeukemia, Lymphocytic, ChronicLymphocyticLymphomaLymphoma, Non-HodgkinLymphoma, Non-hodgkinMultiple Myeloma

Phase 1

Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients

CompletedNCT00562224

Pharmacyclics LLC.Hodgkin Disease, Leukemia, Lymphocytic, Chronic, Lymphoma, Non-hodgkin +2

Start: 2007-11-30End: 2010-09-30Target: 36Updated: 2011-09-28

Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma

CompletedNCT00724984

Pharmacyclics LLC.Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

Start: 2008-07-31Updated: 2014-04-07

PCI-24781 in Combination With Doxorubicin to Treat Sarcoma

CompletedNCT01027910

Massachusetts General HospitalSarcoma

Start: 2009-02-28End: 2015-03-31Updated: 2025-07-24

A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer

CompletedNCT01149668

Pharmacyclics LLC.Hodgkin Disease, Leukemia, Lymphocytic +3

Start: 2010-06-30End: 2013-04-30Updated: 2013-06-19

Related Papers

Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study.

2025-05-30